Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study
Objectives Two oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were to determine the trends in lung cancer burden and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/5/e033427.full |